{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:50:36Z","timestamp":1782859836816,"version":"3.54.5"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12253-4","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:02:44Z","timestamp":1782856964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroinflammation and Tauopathies"],"prefix":"10.1007","volume":"53","author":[{"given":"Marie-Noel","family":"Zeenny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Salame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-8935","authenticated-orcid":false,"given":"Elias","family":"Akoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"12253_CR1","doi-asserted-by":"publisher","first-page":"13982","DOI":"10.1021\/ja305470p","volume":"134","author":"V Daebel","year":"2012","unstructured":"Daebel V et al (2012) beta-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc 134:13982\u201313989. https:\/\/doi.org\/10.1021\/ja305470p","journal-title":"J Am Chem Soc"},{"key":"12253_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165. https:\/\/doi.org\/10.1186\/s12974-023-02853-3","journal-title":"J Neuroinflammation"},{"key":"12253_CR3","doi-asserted-by":"publisher","first-page":"877806","DOI":"10.3389\/fphar.2022.877806","volume":"13","author":"P Zeng","year":"2022","unstructured":"Zeng P et al (2022) A Tau pathogenesis-based network pharmacology approach for exploring the protections of chuanxiong rhizoma in alzheimer\u2019s disease. Front Pharmacol 13:877806. https:\/\/doi.org\/10.3389\/fphar.2022.877806","journal-title":"Front Pharmacol"},{"key":"12253_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/jnen\/nlaa100","volume":"79","author":"SL Forrest","year":"2020","unstructured":"Forrest SL et al (2020) A practical approach to differentiate the frontotemporal tauopathy subtypes. J Neuropathol Exp Neurol 79:1122\u20131126. https:\/\/doi.org\/10.1093\/jnen\/nlaa100","journal-title":"J Neuropathol Exp Neurol"},{"key":"12253_CR5","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/ja312471h","volume":"135","author":"E Akoury","year":"2013","unstructured":"Akoury E et al (2013) Inhibition of tau filament formation by conformational modulation. J Am Chem Soc 135:2853\u20132862. https:\/\/doi.org\/10.1021\/ja312471h","journal-title":"J Am Chem Soc"},{"key":"12253_CR6","unstructured":"Akoury E (2013) Molecular mechanisms of tau protein aggregation inhibition doctorate thesis, University of Goettingen, Germany"},{"key":"12253_CR7","doi-asserted-by":"publisher","first-page":"824888","DOI":"10.3389\/fnins.2022.824888","volume":"16","author":"EF Garland","year":"2022","unstructured":"Garland EF, Hartnell IJ, Boche D (2022) Microglia and astrocyte function and communication: What do we know in humans? Front Neurosci 16:824888. https:\/\/doi.org\/10.3389\/fnins.2022.824888","journal-title":"Front Neurosci"},{"key":"12253_CR8","doi-asserted-by":"publisher","unstructured":"Ruiz-Gabarre D, Carnero-Espejo A, Avila J, Garcia-Escudero V (2022) What\u2019s in a gene? The outstanding diversity of MAPT. Cells 11. https:\/\/doi.org\/10.3390\/cells11050840","DOI":"10.3390\/cells11050840"},{"key":"12253_CR9","doi-asserted-by":"publisher","first-page":"e2200138","DOI":"10.1002\/bies.202200138","volume":"45","author":"A Cario","year":"2023","unstructured":"Cario A, Berger CL (2023) Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative disease. BioEssays 45:e2200138. https:\/\/doi.org\/10.1002\/bies.202200138","journal-title":"BioEssays"},{"key":"12253_CR10","doi-asserted-by":"publisher","first-page":"932541","DOI":"10.3389\/fnagi.2022.932541","volume":"14","author":"A Seitkazina","year":"2022","unstructured":"Seitkazina A et al (2022) The fate of tau aggregates between clearance and transmission. Front Aging Neurosci 14:932541. https:\/\/doi.org\/10.3389\/fnagi.2022.932541","journal-title":"Front Aging Neurosci"},{"key":"12253_CR11","doi-asserted-by":"publisher","unstructured":"Yang J, Zhi W, Wang L (2024) Role of Tau protein in neurodegenerative diseases and development of its targeted drugs: A literature review. Molecules 29. https:\/\/doi.org\/10.3390\/molecules29122812","DOI":"10.3390\/molecules29122812"},{"key":"12253_CR12","doi-asserted-by":"publisher","unstructured":"Ngo V, Duennwald ML (2022) Nrf2 and oxidative stress: A general overview of mechanisms and implications in human disease. Antioxid (Basel) 11. https:\/\/doi.org\/10.3390\/antiox11122345","DOI":"10.3390\/antiox11122345"},{"key":"12253_CR13","doi-asserted-by":"publisher","unstructured":"Navarro E, Esteras N (2024) Multitarget effects of Nrf2 signalling in the brain: Common and specific functions in different cell types. Antioxid (Basel) 13. https:\/\/doi.org\/10.3390\/antiox13121502","DOI":"10.3390\/antiox13121502"},{"key":"12253_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/ars.2023.0234","volume":"38","author":"A Uruno","year":"2023","unstructured":"Uruno A, Yamamoto M (2023) The KEAP1-NRF2 system and neurodegenerative diseases. Antioxid Redox Signal 38:974\u2013988. https:\/\/doi.org\/10.1089\/ars.2023.0234","journal-title":"Antioxid Redox Signal"},{"key":"12253_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H (2023) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Therapy 8:267. https:\/\/doi.org\/10.1038\/s41392-023-01486-5","journal-title":"Signal Transduct Target Therapy"},{"key":"12253_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y (2023) Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation 20:165. https:\/\/doi.org\/10.1186\/s12974-023-02853-3","journal-title":"J Neuroinflammation"},{"key":"12253_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41435-020-00113-5","volume":"21","author":"A Didonna","year":"2020","unstructured":"Didonna A (2020) Tau at the interface between neurodegeneration and neuroinflammation. Genes Immun 21:288\u2013300. https:\/\/doi.org\/10.1038\/s41435-020-00113-5","journal-title":"Genes Immun"},{"key":"12253_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu KM, Yang L, Dong Q, Yu JT (2022) Tauopathies: new perspectives and challenges. Mol Neurodegener 17:28. https:\/\/doi.org\/10.1186\/s13024-022-00533-z","journal-title":"Mol Neurodegener"},{"key":"12253_CR19","doi-asserted-by":"publisher","first-page":"e933084","DOI":"10.12659\/MSM.933084","volume":"27","author":"X Yin","year":"2021","unstructured":"Yin X et al (2021) The role of amyloid-beta and tau in the early pathogenesis of alzheimer\u2019s disease. Med Sci Monit 27:e933084. https:\/\/doi.org\/10.12659\/MSM.933084","journal-title":"Med Sci Monit"},{"key":"12253_CR20","doi-asserted-by":"publisher","first-page":"e70502","DOI":"10.1002\/alz.70502","volume":"21","author":"M Fernandez-Matarrubia","year":"2025","unstructured":"Fernandez-Matarrubia M et al (2025) Early microglial and astrocyte reactivity in preclinical Alzheimer\u2019s disease. Alzheimers Dement 21:e70502. https:\/\/doi.org\/10.1002\/alz.70502","journal-title":"Alzheimers Dement"},{"key":"12253_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 8:359. https:\/\/doi.org\/10.1038\/s41392-023-01588-0","journal-title":"Signal Transduct Target Ther"},{"key":"12253_CR22","doi-asserted-by":"publisher","unstructured":"Szatmari EM et al (2025) Lack of ADAP1\/Centaurin-alpha1 Ameliorates cognitive impairment and neuropathological hallmarks in a mouse model of Alzheimer\u2019s Disease. eNeuro 12 https:\/\/doi.org\/10.1523\/ENEURO.0063-25.2025","DOI":"10.1523\/ENEURO.0063-25.2025"},{"key":"12253_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-021-00488-7","volume":"16","author":"S Qiu","year":"2021","unstructured":"Qiu S et al (2021) Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer\u2019s disease-like neuroinflammation and cognitive impairment. Mol Neurodegener 16:64. https:\/\/doi.org\/10.1186\/s13024-021-00488-7","journal-title":"Mol Neurodegener"},{"key":"12253_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s40478-023-01655-1","volume":"11","author":"KL Fiock","year":"2023","unstructured":"Fiock KL, Hook JN, Hefti MM (2023) Determinants of astrocytic pathology in stem cell models of primary tauopathies. Acta Neuropathol Commun 11:161. https:\/\/doi.org\/10.1186\/s40478-023-01655-1","journal-title":"Acta Neuropathol Commun"},{"key":"12253_CR25","doi-asserted-by":"publisher","first-page":"116232","DOI":"10.1016\/j.celrep.2025.116232","volume":"44","author":"AM Johnson","year":"2025","unstructured":"Johnson AM, Lukens JR (2025) Emerging roles for innate and adaptive immunity in tauopathies. Cell Rep 44:116232. https:\/\/doi.org\/10.1016\/j.celrep.2025.116232","journal-title":"Cell Rep"},{"key":"12253_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH (2023) Neuroinflammation in Alzheimer\u2019s disease: Current progress in molecular signaling and therapeutics. Inflammation 46:1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1","journal-title":"Inflammation"},{"key":"12253_CR27","doi-asserted-by":"publisher","first-page":"1305087","DOI":"10.3389\/fimmu.2024.1305087","volume":"15","author":"C Pallares-Moratalla","year":"2024","unstructured":"Pallares-Moratalla C, Bergers G (2024) The ins and outs of microglial cells in brain health and disease. Front Immunol 15:1305087. https:\/\/doi.org\/10.3389\/fimmu.2024.1305087","journal-title":"Front Immunol"},{"key":"12253_CR28","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.2174\/1570159X19666211202123322","volume":"20","author":"MA Haidar","year":"2022","unstructured":"Haidar MA et al (2022) Crosstalk between microglia and neurons in neurotrauma: An overview of the underlying mechanisms. Curr Neuropharmacol 20:2050\u20132065. https:\/\/doi.org\/10.2174\/1570159X19666211202123322","journal-title":"Curr Neuropharmacol"},{"key":"12253_CR29","doi-asserted-by":"publisher","unstructured":"Szukiewicz D (2024) CX3CL1 (Fractalkine)-CX3CR1 axis in inflammation-induced angiogenesis and tumorigenesis. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25094679","DOI":"10.3390\/ijms25094679"},{"key":"12253_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/glia.24168","volume":"70","author":"J Hirrlinger","year":"2022","unstructured":"Hirrlinger J, Nimmerjahn A (2022) A perspective on astrocyte regulation of neural circuit function and animal behavior. Glia 70:1554\u20131580. https:\/\/doi.org\/10.1002\/glia.24168","journal-title":"Glia"},{"key":"12253_CR31","doi-asserted-by":"publisher","unstructured":"Mahmoud S, Gharagozloo M, Simard C, Gris D (2019) Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells 8. https:\/\/doi.org\/10.3390\/cells8020184","DOI":"10.3390\/cells8020184"},{"key":"12253_CR32","doi-asserted-by":"publisher","unstructured":"Pham C et al (2024) Astrocyte aquaporin mediates a tonic water efflux maintaining brain homeostasis. Elife 13. https:\/\/doi.org\/10.7554\/eLife.95873","DOI":"10.7554\/eLife.95873"},{"key":"12253_CR33","doi-asserted-by":"publisher","first-page":"573256","DOI":"10.3389\/fimmu.2020.573256","volume":"11","author":"M Linnerbauer","year":"2020","unstructured":"Linnerbauer M, Rothhammer V (2020) Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. Front Immunol 11:573256. https:\/\/doi.org\/10.3389\/fimmu.2020.573256","journal-title":"Front Immunol"},{"key":"12253_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW et al (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimers Dement (N Y)"},{"key":"12253_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1474-4422(23)00038-8","volume":"22","author":"C Langworth-Green","year":"2023","unstructured":"Langworth-Green C et al (2023) Chronic effects of inflammation on tauopathies. Lancet Neurol 22:430\u2013442. https:\/\/doi.org\/10.1016\/S1474-4422(23)00038-8","journal-title":"Lancet Neurol"},{"key":"12253_CR36","doi-asserted-by":"publisher","first-page":"742065","DOI":"10.3389\/fnins.2021.742065","volume":"15","author":"L Muzio","year":"2021","unstructured":"Muzio L, Viotti A, Martino G (2021) Microglia in neuroinflammation and neurodegeneration: From understanding to therapy. Front Neurosci 15:742065. https:\/\/doi.org\/10.3389\/fnins.2021.742065","journal-title":"Front Neurosci"},{"key":"12253_CR37","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus H, Heneka MT (2017) Microglia in Alzheimer\u2019s disease. J Clin Invest 127:3240\u20133249. https:\/\/doi.org\/10.1172\/JCI90606","journal-title":"J Clin Invest"},{"key":"12253_CR38","doi-asserted-by":"publisher","unstructured":"Porro C, Cianciulli A, Panaro MA (2020) The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules 10. https:\/\/doi.org\/10.3390\/biom10071017","DOI":"10.3390\/biom10071017"},{"key":"12253_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s41983-023-00751-2","volume":"59","author":"J Limantoro","year":"2023","unstructured":"Limantoro J, de Liyis BG, Sutedja JC (2023) Akt signaling pathway: a potential therapy for Alzheimer\u2019s disease through glycogen synthase kinase 3 beta inhibition. Egypt J Neurol Psychiatry Neurosurg 59:147. https:\/\/doi.org\/10.1186\/s41983-023-00751-2","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"12253_CR40","doi-asserted-by":"publisher","unstructured":"Zhou J et al (2015) Crosstalk Between MAPK\/ERK and PI3K\/AKT signal pathways during brain ischemia\/reperfusion. ASN Neuro 7. https:\/\/doi.org\/10.1177\/1759091415602463","DOI":"10.1177\/1759091415602463"},{"key":"12253_CR41","doi-asserted-by":"publisher","first-page":"707268","DOI":"10.3389\/fcell.2021.707268","volume":"9","author":"H Zhang","year":"2021","unstructured":"Zhang H, Cao Y, Ma L, Wei Y, Li H (2021) Possible mechanisms of Tau Spread and toxicity in alzheimer\u2019s disease. Front Cell Dev Biol 9:707268. https:\/\/doi.org\/10.3389\/fcell.2021.707268","journal-title":"Front Cell Dev Biol"},{"key":"12253_CR42","doi-asserted-by":"publisher","first-page":"108265","DOI":"10.1016\/j.phrs.2026.108265","volume":"230","author":"R Huang","year":"2026","unstructured":"Huang R et al (2026) Ext1-targeted gene therapy ameliorates tauopathy by inhibiting heparan sulfate-dependent tau propagation. Pharmacol Res 230:108265. https:\/\/doi.org\/10.1016\/j.phrs.2026.108265","journal-title":"Pharmacol Res"},{"key":"12253_CR43","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.29924","volume":"39","author":"M Malpetti","year":"2024","unstructured":"Malpetti M et al (2024) Neuroinflammation Parallels 18F-PI-2620 positron emission tomography patterns in primary 4-repeat tauopathies. Mov Disord 39:1480\u20131492. https:\/\/doi.org\/10.1002\/mds.29924","journal-title":"Mov Disord"},{"key":"12253_CR44","doi-asserted-by":"publisher","first-page":"104988","DOI":"10.1016\/j.yexmp.2025.104988","volume":"143","author":"I Alsharif","year":"2025","unstructured":"Alsharif I (2025) NVP-BEZ235 enhances autophagy and ameliorates cognitive deficits by targeting tauopathies. Exp Mol Pathol 143:104988. https:\/\/doi.org\/10.1016\/j.yexmp.2025.104988","journal-title":"Exp Mol Pathol"},{"key":"12253_CR45","doi-asserted-by":"publisher","first-page":"fcag084","DOI":"10.1093\/braincomms\/fcag084","volume":"8","author":"SL Forrest","year":"2026","unstructured":"Forrest SL et al (2026) Distinct neuroinflammatory profiles in progressive supranuclear palsy associated with HLA haplotypes. Brain Commun 8:fcag084. https:\/\/doi.org\/10.1093\/braincomms\/fcag084","journal-title":"Brain Commun"},{"key":"12253_CR46","doi-asserted-by":"publisher","unstructured":"Angelopoulou E, Papatriantafyllou J, Papageorgiou S, Villa C (2026) Elucidating the neurobiological underpinnings of mild behavioral impairment in tauopathies: Clinical and Molecular Insights. Int J Mol Sci 27. https:\/\/doi.org\/10.3390\/ijms27073341","DOI":"10.3390\/ijms27073341"},{"key":"12253_CR47","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/brain\/awaa033","volume":"143","author":"WR Bevan-Jones","year":"2020","unstructured":"Bevan-Jones WR et al (2020) Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain 143:1010\u20131026. https:\/\/doi.org\/10.1093\/brain\/awaa033","journal-title":"Brain"},{"key":"12253_CR48","doi-asserted-by":"publisher","unstructured":"Kubiak A et al (2026) Astrocytic contributions to the pathogenesis of chronic traumatic encephalopathy: a scoping review. Chin Neurosurg J 12. https:\/\/doi.org\/10.1186\/s41016-026-00434-w","DOI":"10.1186\/s41016-026-00434-w"},{"key":"12253_CR49","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1177\/13872877251352194","volume":"106","author":"N Moreira","year":"2025","unstructured":"Moreira N, Piassi LO, Lima J, Passos GA (2025) Sakamoto-Hojo, E. T. PTEN inhibition induces neuronal differentiation and neuritogenesis in SH-SY5Y cells via AKT signaling pathway. J Alzheimers Dis 106:1436\u20131451. https:\/\/doi.org\/10.1177\/13872877251352194","journal-title":"J Alzheimers Dis"},{"key":"12253_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fendo.2020.00403","volume":"11","author":"RM Barker","year":"2020","unstructured":"Barker RM, Holly JMP, Biernacka KM, Allen-Birt SJ, Perks CM (2020) Mini review: Opposing pathologies in cancer and alzheimer\u2019s disease: Does the PI3K\/Akt Pathway Provide Clues? Front Endocrinol (Lausanne) 11:403. https:\/\/doi.org\/10.3389\/fendo.2020.00403","journal-title":"Front Endocrinol (Lausanne)"},{"key":"12253_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JAD-2011-110104","volume":"25","author":"G Yin","year":"2011","unstructured":"Yin G et al (2011) Upregulation of AKT attenuates amyloid-beta-induced cell apoptosis. J Alzheimers Dis 25:337\u2013345. https:\/\/doi.org\/10.3233\/JAD-2011-110104","journal-title":"J Alzheimers Dis"},{"key":"12253_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13041-019-0525-5","volume":"12","author":"L Jia","year":"2019","unstructured":"Jia L, Pina-Crespo J, Li Y (2019) Restoring Wnt\/beta-catenin signaling is a promising therapeutic strategy for Alzheimer\u2019s disease. Mol Brain 12:104. https:\/\/doi.org\/10.1186\/s13041-019-0525-5","journal-title":"Mol Brain"},{"key":"12253_CR53","doi-asserted-by":"publisher","unstructured":"Anand AA, Khan M, V, M., Kar D (2023) The molecular basis of wnt\/beta-catenin signaling pathways in neurodegenerative diseases. Int J Cell Biol 9296092 (2023). https:\/\/doi.org\/10.1155\/2023\/9296092","DOI":"10.1155\/2023\/9296092"},{"key":"12253_CR54","doi-asserted-by":"publisher","first-page":"102058","DOI":"10.1016\/j.isci.2021.102058","volume":"24","author":"AC Amaral","year":"2021","unstructured":"Amaral AC et al (2021) Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3beta) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation. iScience 24:102058. https:\/\/doi.org\/10.1016\/j.isci.2021.102058","journal-title":"iScience"},{"key":"12253_CR55","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/pro.2911","volume":"25","author":"E Akoury","year":"2016","unstructured":"Akoury E et al (2016) Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer. Protein Sci 25:1010\u20131020. https:\/\/doi.org\/10.1002\/pro.2911","journal-title":"Protein Sci"},{"key":"12253_CR56","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2014.01.037","volume":"156","author":"GE Karagoz","year":"2014","unstructured":"Karagoz GE et al (2014) Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156:963\u2013974. https:\/\/doi.org\/10.1016\/j.cell.2014.01.037","journal-title":"Cell"},{"key":"12253_CR57","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.4103\/1673-5374.238606","volume":"13","author":"C Tapia-Rojas","year":"2018","unstructured":"Tapia-Rojas C, Inestrosa NC (2018) Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer\u2019s disease. Neural Regen Res 13:1705\u20131710. https:\/\/doi.org\/10.4103\/1673-5374.238606","journal-title":"Neural Regen Res"},{"key":"12253_CR58","doi-asserted-by":"publisher","first-page":"e2250266","DOI":"10.1002\/eji.202250266","volume":"53","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Lukens JR (2023) The innate immune response in tauopathies. Eur J Immunol 53:e2250266. https:\/\/doi.org\/10.1002\/eji.202250266","journal-title":"Eur J Immunol"},{"key":"12253_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-022-02528-y","volume":"145","author":"S Moonen","year":"2023","unstructured":"Moonen S et al (2023) Pyroptosis in Alzheimer\u2019s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol 145:175\u2013195. https:\/\/doi.org\/10.1007\/s00401-022-02528-y","journal-title":"Acta Neuropathol"},{"key":"12253_CR60","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.3390\/ijms24076701","volume":"24","author":"R Kircheis","year":"2023","unstructured":"Kircheis R, Planz O (2023) The role of toll-like receptors (TLRs) and their related signaling pathways in viral infection and inflammation. Int J Mol Sci 24:6701. https:\/\/doi.org\/10.3390\/ijms24076701","journal-title":"Int J Mol Sci"},{"key":"12253_CR61","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki T, Kawai T (2014) Toll-like receptor signaling pathways. Front Immunol 5:461. https:\/\/doi.org\/10.3389\/fimmu.2014.00461","journal-title":"Front Immunol"},{"key":"12253_CR62","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4103\/1673-5374.303016","volume":"16","author":"ML Dallas","year":"2021","unstructured":"Dallas ML, Widera D (2021) TLR2 and TLR4-mediated inflammation in Alzheimer\u2019s disease: self-defense or sabotage? Neural Regen Res 16:1552\u20131553. https:\/\/doi.org\/10.4103\/1673-5374.303016","journal-title":"Neural Regen Res"},{"key":"12253_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.yexcr.2017.07.032","volume":"359","author":"Y Sun","year":"2017","unstructured":"Sun Y et al (2017) High-glucose induces tau hyperphosphorylation through activation of TLR9-P38MAPK pathway. Exp Cell Res 359:312\u2013318. https:\/\/doi.org\/10.1016\/j.yexcr.2017.07.032","journal-title":"Exp Cell Res"},{"key":"12253_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1326-6-69","volume":"6","author":"H Jiang","year":"2011","unstructured":"Jiang H et al (2011) Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer\u2019s disease. Mol Neurodegeneration 6:69. https:\/\/doi.org\/10.1186\/1750-1326-6-69","journal-title":"Mol Neurodegeneration"},{"key":"12253_CR65","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C et al (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575:669\u2013673. https:\/\/doi.org\/10.1038\/s41586-019-1769-z","journal-title":"Nature"},{"key":"12253_CR66","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-018-01957-y","volume":"137","author":"I-C Stancu","year":"2019","unstructured":"Stancu I-C et al (2019) Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol 137:599\u2013617. https:\/\/doi.org\/10.1007\/s00401-018-01957-y","journal-title":"Acta Neuropathol"},{"key":"12253_CR67","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT (2024) Innate immune activation in neurodegenerative diseases. Immunity 57:790\u2013814. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.010","journal-title":"Immunity"},{"key":"12253_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0197-4580(01)00285-8","volume":"23","author":"E Tarkowski","year":"2002","unstructured":"Tarkowski E et al (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer\u2019s disease and vascular dementia. Neurobiol Aging 23:237\u2013243. https:\/\/doi.org\/10.1016\/s0197-4580(01)00285-8","journal-title":"Neurobiol Aging"},{"key":"12253_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1326-6-69","volume":"6","author":"H Jiang","year":"2011","unstructured":"Jiang H et al (2011) Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer\u2019s disease. Mol Neurodegener 6:69. https:\/\/doi.org\/10.1186\/1750-1326-6-69","journal-title":"Mol Neurodegener"},{"key":"12253_CR70","doi-asserted-by":"publisher","first-page":"e092843","DOI":"10.1002\/alz.092843","volume":"20","author":"ICB Burgos","year":"2024","unstructured":"Burgos ICB et al (2024) Decreased levels of CSF CXCL8 in clinical and biological profiles of Alzheimer\u2019s disease: results of a cohort of Brazilian older adults. Alzheimer\u2019s Dement 20:e092843. https:\/\/doi.org\/10.1002\/alz.092843","journal-title":"Alzheimer\u2019s Dement"},{"key":"12253_CR71","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cells10071652","volume":"10","author":"C Panda","year":"2021","unstructured":"Panda C et al (2021) Aggregated Tau-PHF6 (VQIVYK) Potentiates NLRP3 inflammasome expression and autophagy in human microglial cells. Cells 10:1652. https:\/\/doi.org\/10.3390\/cells10071652","journal-title":"Cells"},{"key":"12253_CR72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A (2021) The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol 21:548\u2013569. https:\/\/doi.org\/10.1038\/s41577-021-00524-z","journal-title":"Nat Rev Immunol"},{"key":"12253_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13024-023-00672-x","volume":"18","author":"Y Huang","year":"2023","unstructured":"Huang Y, Liu B, Sinha SC, Amin S, Gan L (2023) Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Mol Neurodegener 18:79. https:\/\/doi.org\/10.1186\/s13024-023-00672-x","journal-title":"Mol Neurodegener"},{"key":"12253_CR74","doi-asserted-by":"publisher","first-page":"e14671","DOI":"10.1111\/cns.14671","volume":"30","author":"X Guo","year":"2024","unstructured":"Guo X et al (2024) The cytosolic DNA-sensing cGAS-STING pathway in neurodegenerative diseases. CNS Neurosci Ther 30:e14671. https:\/\/doi.org\/10.1111\/cns.14671","journal-title":"CNS Neurosci Ther"},{"key":"12253_CR75","doi-asserted-by":"publisher","first-page":"e2250266","DOI":"10.1002\/eji.202250266","volume":"53","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Lukens JR (2023) The innate immune response in tauopathies. Eur J Immunol 53:e2250266. https:\/\/doi.org\/10.1002\/eji.202250266","journal-title":"Eur J Immunol"},{"key":"12253_CR76","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1038\/cddis.2011.50","volume":"2","author":"CJ Garwood","year":"2011","unstructured":"Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2:e167. https:\/\/doi.org\/10.1038\/cddis.2011.50","journal-title":"Cell Death Dis"},{"key":"12253_CR77","doi-asserted-by":"publisher","unstructured":"Qin C, Li Y, Wang K (2021) Novel balance mechanism participates in stem cell therapy to alleviate neuropathology and cognitive impairment in animal models with alzheimer\u2019s disease. Cells 10. https:\/\/doi.org\/10.3390\/cells10102757","DOI":"10.3390\/cells10102757"},{"key":"12253_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-022-00552-w","volume":"17","author":"JV Haure-Mirande","year":"2022","unstructured":"Haure-Mirande JV, Audrain M, Ehrlich ME, Gandy S, Microglial (2022) TYROBP\/DAP12 in Alzheimer\u2019s disease: Transduction of physiological and pathological signals across TREM2. Mol Neurodegener 17:55. https:\/\/doi.org\/10.1186\/s13024-022-00552-w","journal-title":"Mol Neurodegener"},{"key":"12253_CR79","doi-asserted-by":"publisher","unstructured":"Wang S et al (2022) TREM2 drives microglia response to amyloid-beta via SYK-dependent and -independent pathways. Cell 185(4153\u20134169 e4119). https:\/\/doi.org\/10.1016\/j.cell.2022.09.033","DOI":"10.1016\/j.cell.2022.09.033"},{"key":"12253_CR80","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13024-022-00545-9","volume":"17","author":"SS Puntambekar","year":"2022","unstructured":"Puntambekar SS et al (2022) CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer\u2019s disease. Mol Neurodegener 17:47. https:\/\/doi.org\/10.1186\/s13024-022-00545-9","journal-title":"Mol Neurodegener"},{"key":"12253_CR81","doi-asserted-by":"publisher","unstructured":"Gutierrez IL et al (2025) CX3CL1 Regulation of gliosis in neuroinflammatory and neuroprotective processes. Int J Mol Sci 26. https:\/\/doi.org\/10.3390\/ijms26030959","DOI":"10.3390\/ijms26030959"},{"key":"12253_CR82","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fncel.2018.00258","volume":"12","author":"ME Haque","year":"2018","unstructured":"Haque ME, Kim IS, Jakaria M, Akther M, Choi DK (2018) Importance of GPCR-mediated microglial activation in alzheimer\u2019s disease. Front Cell Neurosci 12:258. https:\/\/doi.org\/10.3389\/fncel.2018.00258","journal-title":"Front Cell Neurosci"},{"key":"12253_CR83","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/febs.15861","volume":"289","author":"ES Wickstead","year":"2022","unstructured":"Wickstead ES, Irving MA, Getting SJ, McArthur S (2022) Exploiting formyl peptide receptor 2 to promote microglial resolution: a new approach to Alzheimer\u2019s disease treatment. FEBS J 289:1801\u20131822. https:\/\/doi.org\/10.1111\/febs.15861","journal-title":"FEBS J"},{"key":"12253_CR84","doi-asserted-by":"publisher","unstructured":"Chen Y et al (2022) Correction: Chen. The Chemerin\/CMKLR1 axis is involved in the recruitment of microglia to Abeta deposition through p38 MAPK pathway. Int. J. Mol. Sci. 23, 9041. Int J Mol Sci 24 (2022). https:\/\/doi.org\/10.3390\/ijms24010506","DOI":"10.3390\/ijms24010506"},{"key":"12253_CR85","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H (2020) Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 5:209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6","journal-title":"Signal Transduct Target Ther"},{"key":"12253_CR86","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ et al (2020) ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med 19:1997\u20132007. https:\/\/doi.org\/10.3892\/etm.2020.8454","journal-title":"Exp Ther Med"},{"key":"12253_CR87","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41420-021-00481-5","volume":"7","author":"S Jiang","year":"2021","unstructured":"Jiang S et al (2021) Silencing TAK1 reduces MAPKs-MMP2\/9 expression to reduce inflammation-driven neurohistological disruption post spinal cord injury. Cell Death Discov 7:96. https:\/\/doi.org\/10.1038\/s41420-021-00481-5","journal-title":"Cell Death Discov"},{"key":"12253_CR88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10571-022-01191-x","volume":"43","author":"MR Khezri","year":"2023","unstructured":"Khezri MR, Yousefi K, Esmaeili A, Ghasemnejad-Berenji M (2023) The role of ERK1\/2 pathway in the pathophysiology of alzheimer\u2019s disease: An overview and update on new developments. Cell Mol Neurobiol 43:177\u2013191. https:\/\/doi.org\/10.1007\/s10571-022-01191-x","journal-title":"Cell Mol Neurobiol"},{"key":"12253_CR89","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-023-02751-8","volume":"20","author":"M Kapoor","year":"2023","unstructured":"Kapoor M, Chinnathambi S (2023) TGF-beta1 signalling in Alzheimer\u2019s pathology and cytoskeletal reorganization: a specialized Tau perspective. J Neuroinflammation 20:72. https:\/\/doi.org\/10.1186\/s12974-023-02751-8","journal-title":"J Neuroinflammation"},{"key":"12253_CR90","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1093\/hmg\/ddv135","volume":"24","author":"SN Fontaine","year":"2015","unstructured":"Fontaine SN et al (2015) The active Hsc70\/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet 24:3971\u20133981. https:\/\/doi.org\/10.1093\/hmg\/ddv135","journal-title":"Hum Mol Genet"},{"key":"12253_CR91","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.12-220889","volume":"27","author":"UK Jinwal","year":"2013","unstructured":"Jinwal UK et al (2013) Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J 27:1450\u20131459. https:\/\/doi.org\/10.1096\/fj.12-220889","journal-title":"FASEB J"},{"key":"12253_CR92","doi-asserted-by":"publisher","unstructured":"Aranda-Abreu GE et al (2026) Alzheimer\u2019s disease as a disorder of neuroimmune dysregulation. Neurol Int 18. https:\/\/doi.org\/10.3390\/neurolint18020037","DOI":"10.3390\/neurolint18020037"},{"key":"12253_CR93","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.pneurobio.2022.102306","volume":"216","author":"KF Odfalk","year":"2022","unstructured":"Odfalk KF, Bieniek KF, Hopp SC, Microglia (2022) Friend and foe in tauopathy. Prog Neurobiol 216:102306. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102306","journal-title":"Prog Neurobiol"},{"key":"12253_CR94","first-page":"115","volume":"2","author":"CL Gao","year":"2025","unstructured":"Gao CL, Chen Z, Gan Y, He R, Han X (2025) The spectrum of microglia: Decoding heterogeneity and plasticity for therapeutic gain in neurological disorders. Neuropharmacol Therapy 2:115\u2013132","journal-title":"Neuropharmacol Therapy"},{"key":"12253_CR95","doi-asserted-by":"publisher","first-page":"106942","DOI":"10.1016\/j.nbd.2025.106942","volume":"211","author":"B Spencer","year":"2025","unstructured":"Spencer B, Schueler A, Sung D, Rissman RA (2025) Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology. Neurobiol Dis 211:106942. https:\/\/doi.org\/10.1016\/j.nbd.2025.106942","journal-title":"Neurobiol Dis"},{"key":"12253_CR96","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.14283\/jpad.2024.164","volume":"11","author":"M Lin","year":"2024","unstructured":"Lin M, Yu JX, Zhang WX, Lao FX, Huang HC (2024) Roles of TREM2 in the pathological mechanism and the therapeutic strategies of alzheimer\u2019s disease. J Prev Alzheimers Dis 11:1682\u20131695. https:\/\/doi.org\/10.14283\/jpad.2024.164","journal-title":"J Prev Alzheimers Dis"},{"key":"12253_CR97","doi-asserted-by":"publisher","first-page":"888989","DOI":"10.3389\/fnagi.2022.888989","volume":"14","author":"HZ Long","year":"2022","unstructured":"Long HZ et al (2022) The role of microglia in alzheimer\u2019s disease from the perspective of immune inflammation and iron metabolism. Front Aging Neurosci 14:888989. https:\/\/doi.org\/10.3389\/fnagi.2022.888989","journal-title":"Front Aging Neurosci"},{"key":"12253_CR98","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1055\/s-0044-1790283","volume":"11","author":"E Meer","year":"2024","unstructured":"Meer E (2024) Role of noncoding RNAs in modulating microglial phenotype. Glob Med Genet 11:304\u2013311. https:\/\/doi.org\/10.1055\/s-0044-1790283","journal-title":"Glob Med Genet"},{"key":"12253_CR99","doi-asserted-by":"publisher","unstructured":"Bivona G et al (2023) Microglial activation and priming in alzheimer\u2019s disease: State of the art and future perspectives. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24010884","DOI":"10.3390\/ijms24010884"},{"key":"12253_CR100","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fimmu.2020.00493","volume":"11","author":"C Lauro","year":"2020","unstructured":"Lauro C, Limatola C (2020) Metabolic reprograming of microglia in the regulation of the innate inflammatory response. Front Immunol 11:493. https:\/\/doi.org\/10.3389\/fimmu.2020.00493","journal-title":"Front Immunol"},{"key":"12253_CR101","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s10571-023-01376-y","volume":"43","author":"J Miao","year":"2023","unstructured":"Miao J et al (2023) Microglial metabolic reprogramming: Emerging insights and therapeutic strategies in neurodegenerative diseases. Cell Mol Neurobiol 43:3191\u20133210. https:\/\/doi.org\/10.1007\/s10571-023-01376-y","journal-title":"Cell Mol Neurobiol"},{"key":"12253_CR102","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2025.0484","author":"M Bentivegna","year":"2025","unstructured":"Bentivegna M et al (2025) Amyloid beta regulates astrocytic glucose metabolism and insulin signaling in experimental models of alzheimer\u2019s disease. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2025.0484","journal-title":"Aging Dis"},{"key":"12253_CR103","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.14336\/AD.2023.0807","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang Q, Wang Y, Chen S, Liang F (2024) Glycometabolic reprogramming of microglia in neurodegenerative diseases: Insights from neuroinflammation. Aging Dis 15:1155\u20131175. https:\/\/doi.org\/10.14336\/AD.2023.0807","journal-title":"Aging Dis"},{"key":"12253_CR104","doi-asserted-by":"publisher","unstructured":"Dutta D et al (2023) Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer\u2019s disease-related mouse models. J Clin Invest 133. https:\/\/doi.org\/10.1172\/JCI161987","DOI":"10.1172\/JCI161987"},{"key":"12253_CR105","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11011-025-01739-y","volume":"40","author":"MM Shokr","year":"2025","unstructured":"Shokr MM (2025) Rewiring brain immunity: targeting microglial metabolism for neuroprotection in neurodegenerative disorders. Metab Brain Dis 40:326. https:\/\/doi.org\/10.1007\/s11011-025-01739-y","journal-title":"Metab Brain Dis"},{"key":"12253_CR106","doi-asserted-by":"publisher","first-page":"150","DOI":"10.20517\/2347-8659.2020.07","volume":"7","author":"GJ Harry","year":"2020","unstructured":"Harry GJ, Childers G, Giridharan S, Hernandes IL (2020) An association between mitochondria and microglia effector function. What do we think we know? Neuroimmunol Neuroinflamm 7:150\u2013165. https:\/\/doi.org\/10.20517\/2347-8659.2020.07","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"12253_CR107","doi-asserted-by":"publisher","first-page":"105684","DOI":"10.1016\/j.nbd.2022.105684","volume":"167","author":"B Kenkhuis","year":"2022","unstructured":"Kenkhuis B et al (2022) Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer\u2019s disease. Neurobiol Dis 167:105684. https:\/\/doi.org\/10.1016\/j.nbd.2022.105684","journal-title":"Neurobiol Dis"},{"key":"12253_CR108","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/glia.70078","volume":"73","author":"AO Lopez-Ortiz","year":"2025","unstructured":"Lopez-Ortiz AO et al (2025) Transcriptional regulation of microglial metabolic and activation states by P2RY12. Glia 73:2464\u20132482. https:\/\/doi.org\/10.1002\/glia.70078","journal-title":"Glia"},{"key":"12253_CR109","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C et al (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575:669\u2013673. https:\/\/doi.org\/10.1038\/s41586-019-1769-z","journal-title":"Nature"},{"key":"12253_CR110","doi-asserted-by":"publisher","first-page":"100242","DOI":"10.1016\/j.bbih.2021.100242","volume":"14","author":"Z Amro","year":"2021","unstructured":"Amro Z, Yool AJ, Collins-Praino LE (2021) The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. Brain Behav Immun Health 14:100242. https:\/\/doi.org\/10.1016\/j.bbih.2021.100242","journal-title":"Brain Behav Immun Health"},{"key":"12253_CR111","doi-asserted-by":"publisher","first-page":"974414","DOI":"10.3389\/fnagi.2022.974414","volume":"14","author":"NA Jackson","year":"2022","unstructured":"Jackson NA, Guerrero-Munoz MJ, Castillo-Carranza DL (2022) The prion-like transmission of tau oligomers via exosomes. Front Aging Neurosci 14:974414. https:\/\/doi.org\/10.3389\/fnagi.2022.974414","journal-title":"Front Aging Neurosci"},{"key":"12253_CR112","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1111\/febs.16055","volume":"289","author":"JC Polanco","year":"2022","unstructured":"Polanco JC, Gotz J (2022) Exosomal and vesicle-free tau seeds-propagation and convergence in endolysosomal permeabilization. FEBS J 289:6891\u20136907. https:\/\/doi.org\/10.1111\/febs.16055","journal-title":"FEBS J"},{"key":"12253_CR113","doi-asserted-by":"publisher","first-page":"e12025","DOI":"10.15252\/emmm.202012025","volume":"12","author":"P Chastagner","year":"2020","unstructured":"Chastagner P et al (2020) Fate and propagation of endogenously formed Tau aggregates in neuronal cells. EMBO Mol Med 12:e12025. https:\/\/doi.org\/10.15252\/emmm.202012025","journal-title":"EMBO Mol Med"},{"key":"12253_CR114","doi-asserted-by":"publisher","unstructured":"Dias G, Hayashide LS, Pessoa B, Diniz LP, Pontes B (2026) Tunneling nanotubes in astrocyte-neuron crosstalk: From intercellular communication and pathological spread to mechanobiological and bio-inspired approaches. Brain Sci 16. https:\/\/doi.org\/10.3390\/brainsci16020138","DOI":"10.3390\/brainsci16020138"},{"key":"12253_CR115","doi-asserted-by":"publisher","unstructured":"Kotarba S et al (2024) Potential Mechanisms of tunneling nanotube formation and their role in pathology spread in alzheimer\u2019s disease and other proteinopathies. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms251910797","DOI":"10.3390\/ijms251910797"},{"key":"12253_CR116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00018-021-04040-0","volume":"79","author":"A Raghavan","year":"2021","unstructured":"Raghavan A, Rao P, Neuzil J, Pountney DL, Nath S (2021) Oxidative stress and Rho GTPases in the biogenesis of tunnelling nanotubes: implications in disease and therapy. Cell Mol Life Sci 79:36. https:\/\/doi.org\/10.1007\/s00018-021-04040-0","journal-title":"Cell Mol Life Sci"},{"key":"12253_CR117","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13024-021-00447-2","volume":"16","author":"K Clayton","year":"2021","unstructured":"Clayton K et al (2021) Correction to: Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol Neurodegener 16:24. https:\/\/doi.org\/10.1186\/s13024-021-00447-2","journal-title":"Mol Neurodegener"},{"key":"12253_CR118","doi-asserted-by":"publisher","first-page":"101272","DOI":"10.1016\/j.arr.2021.101272","volume":"67","author":"J Zhao","year":"2021","unstructured":"Zhao J, Wu H, Tang XQ (2021) Tau internalization: A complex step in tau propagation. Ageing Res Rev 67:101272. https:\/\/doi.org\/10.1016\/j.arr.2021.101272","journal-title":"Ageing Res Rev"},{"key":"12253_CR119","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00401-015-1462-8","volume":"130","author":"W Scheper","year":"2015","unstructured":"Scheper W, Hoozemans JJ (2015) The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. Acta Neuropathol 130:315\u2013331. https:\/\/doi.org\/10.1007\/s00401-015-1462-8","journal-title":"Acta Neuropathol"},{"key":"12253_CR120","doi-asserted-by":"publisher","first-page":"104255","DOI":"10.1016\/j.phrs.2019.104255","volume":"145","author":"M Ettcheto","year":"2019","unstructured":"Ettcheto M et al (2019) A metabolic perspective of late onset Alzheimer\u2019s disease. Pharmacol Res 145:104255. https:\/\/doi.org\/10.1016\/j.phrs.2019.104255","journal-title":"Pharmacol Res"},{"key":"12253_CR121","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41419-022-05153-5","volume":"13","author":"A Ajoolabady","year":"2022","unstructured":"Ajoolabady A, Lindholm D, Ren J, Pratico D (2022) ER stress and UPR in Alzheimer\u2019s disease: mechanisms, pathogenesis, treatments. Cell Death Dis 13:706. https:\/\/doi.org\/10.1038\/s41419-022-05153-5","journal-title":"Cell Death Dis"},{"key":"12253_CR122","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ni.3102","volume":"16","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Golenbock DT, Latz E (2015) Innate immunity in Alzheimer\u2019s disease. Nat Immunol 16:229\u2013236. https:\/\/doi.org\/10.1038\/ni.3102","journal-title":"Nat Immunol"},{"key":"12253_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/wnl.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139. https:\/\/doi.org\/10.1212\/wnl.47.1.1","journal-title":"Neurology"},{"key":"12253_CR124","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353:777\u2013783. https:\/\/doi.org\/10.1126\/science.aag2590","journal-title":"Science"},{"key":"12253_CR125","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer\u2019s disease: Current evidence and future directions. Alzheimers Dement 12:719\u2013732. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.010","journal-title":"Alzheimers Dement"},{"key":"12253_CR126","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-2094-3-5","volume":"3","author":"WS Griffin","year":"2006","unstructured":"Griffin WS, Liu L, Li Y, Mrak RE, Barger SW (2006) Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 3:5. https:\/\/doi.org\/10.1186\/1742-2094-3-5","journal-title":"J Neuroinflammation"},{"key":"12253_CR127","doi-asserted-by":"publisher","unstructured":"Malorny N et al (2026) TNF-alpha and IFN-gamma impair neural oscillations and induce neurodegeneration by microglial nitric oxide, metabolic and oxidative stress. J Neuroinflammation 23. https:\/\/doi.org\/10.1186\/s12974-026-03835-x","DOI":"10.1186\/s12974-026-03835-x"},{"key":"12253_CR128","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/alz.13699","volume":"20","author":"SM Rossano","year":"2024","unstructured":"Rossano SM et al (2024) Microglia measured by TSPO PET are associated with Alzheimer\u2019s disease pathology and mediate key steps in a disease progression model. Alzheimers Dement 20:2397\u20132407. https:\/\/doi.org\/10.1002\/alz.13699","journal-title":"Alzheimers Dement"},{"key":"12253_CR129","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40336-016-0171-1","volume":"4","author":"A Gerhard","year":"2016","unstructured":"Gerhard A (2016) TSPO imaging in parkinsonian disorders. Clin Transl Imaging 4:183\u2013190. https:\/\/doi.org\/10.1007\/s40336-016-0171-1","journal-title":"Clin Transl Imaging"},{"key":"12253_CR130","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/jcbfm.2012.46","volume":"32","author":"R Mizrahi","year":"2012","unstructured":"Mizrahi R et al (2012) Translocator protein (18\u00a0kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. J Cereb Blood Flow Metab 32:968\u2013972. https:\/\/doi.org\/10.1038\/jcbfm.2012.46","journal-title":"J Cereb Blood Flow Metab"},{"key":"12253_CR131","doi-asserted-by":"publisher","unstructured":"Dupont AC et al (2017) Translocator Protein-18\u00a0kDa (TSPO) Positron Emission Tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci 18. https:\/\/doi.org\/10.3390\/ijms18040785","DOI":"10.3390\/ijms18040785"},{"key":"12253_CR132","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-018-01957-y","volume":"137","author":"IC Stancu","year":"2019","unstructured":"Stancu IC et al (2019) Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol 137:599\u2013617. https:\/\/doi.org\/10.1007\/s00401-018-01957-y","journal-title":"Acta Neuropathol"},{"key":"12253_CR133","doi-asserted-by":"publisher","first-page":"952211","DOI":"10.3389\/fphar.2022.952211","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu X, Yu C, He W (2022) Emerging trends and hot spots of NLRP3 inflammasome in neurological diseases: A bibliometric analysis. Front Pharmacol 13:952211. https:\/\/doi.org\/10.3389\/fphar.2022.952211","journal-title":"Front Pharmacol"},{"key":"12253_CR134","doi-asserted-by":"publisher","first-page":"e14818","DOI":"10.1111\/cns.14818","volume":"30","author":"J Zhao","year":"2024","unstructured":"Zhao J et al (2024) GSK3: A potential target and pending issues for treatment of Alzheimer\u2019s disease. CNS Neurosci Ther 30:e14818. https:\/\/doi.org\/10.1111\/cns.14818","journal-title":"CNS Neurosci Ther"},{"key":"12253_CR135","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fnmol.2011.00024","volume":"4","author":"M Medina","year":"2011","unstructured":"Medina M, Garrido JJ, Wandosell FG (2011) Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci 4:24. https:\/\/doi.org\/10.3389\/fnmol.2011.00024","journal-title":"Front Mol Neurosci"},{"key":"12253_CR136","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa E et al (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29:470\u2013478. https:\/\/doi.org\/10.1002\/mds.25824","journal-title":"Mov Disord"},{"key":"12253_CR137","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.25815","volume":"29","author":"GU Hoglinger","year":"2014","unstructured":"Hoglinger GU et al (2014) Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 29:479\u2013487. https:\/\/doi.org\/10.1002\/mds.25815","journal-title":"Mov Disord"},{"key":"12253_CR138","doi-asserted-by":"publisher","first-page":"1576020","DOI":"10.3389\/fnagi.2025.1576020","volume":"17","author":"YN Ma","year":"2025","unstructured":"Ma YN et al (2025) The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: insights from the INVOKE-2 study. Front Aging Neurosci 17:1576020. https:\/\/doi.org\/10.3389\/fnagi.2025.1576020","journal-title":"Front Aging Neurosci"},{"key":"12253_CR139","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M (2018) TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14:667\u2013675. https:\/\/doi.org\/10.1038\/s41582-018-0072-1","journal-title":"Nat Rev Neurol"},{"key":"12253_CR140","doi-asserted-by":"publisher","unstructured":"Choi EH, Kim MH, Park SJ (2024) Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25147952","DOI":"10.3390\/ijms25147952"},{"key":"12253_CR141","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","volume":"18","author":"A Cuadrado","year":"2019","unstructured":"Cuadrado A et al (2019) Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 18:295\u2013317. https:\/\/doi.org\/10.1038\/s41573-018-0008-x","journal-title":"Nat Rev Drug Discov"},{"key":"12253_CR142","doi-asserted-by":"publisher","first-page":"e2348","DOI":"10.6061\/clinics\/2021\/e2348","volume":"76","author":"L Yang","year":"2021","unstructured":"Yang L, Liu Y, Wang Y, Li J, Liu N (2021) Azeliragon ameliorates Alzheimer\u2019s disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway. Clin (Sao Paulo) 76:e2348. https:\/\/doi.org\/10.6061\/clinics\/2021\/e2348","journal-title":"Clin (Sao Paulo)"},{"key":"12253_CR143","doi-asserted-by":"publisher","first-page":"e2400459","DOI":"10.1002\/ardp.202400459","volume":"357","author":"Y Zheng","year":"2024","unstructured":"Zheng Y et al (2024) MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions. Arch Pharm (Weinheim) 357:e2400459. https:\/\/doi.org\/10.1002\/ardp.202400459","journal-title":"Arch Pharm (Weinheim)"},{"key":"12253_CR144","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1517\/13543780903066780","volume":"18","author":"BP Imbimbo","year":"2009","unstructured":"Imbimbo BP (2009) An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer\u2019s disease. Expert Opin Investig Drugs 18:1147\u20131168. https:\/\/doi.org\/10.1517\/13543780903066780","journal-title":"Expert Opin Investig Drugs"},{"key":"12253_CR145","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"L Escribano","year":"2010","unstructured":"Escribano L et al (2010) Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35:1593\u20131604. https:\/\/doi.org\/10.1038\/npp.2010.32","journal-title":"Neuropsychopharmacology"},{"key":"12253_CR146","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14728222.2011.594043","volume":"15","author":"S Mandrekar-Colucci","year":"2011","unstructured":"Mandrekar-Colucci S, Landreth GE (2011) Nuclear receptors as therapeutic targets for Alzheimer\u2019s disease. Expert Opin Ther Targets 15:1085\u20131097. https:\/\/doi.org\/10.1517\/14728222.2011.594043","journal-title":"Expert Opin Ther Targets"},{"key":"12253_CR147","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"M Gold","year":"2010","unstructured":"Gold M et al (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131\u2013146. https:\/\/doi.org\/10.1159\/000318845","journal-title":"Dement Geriatr Cogn Disord"},{"key":"12253_CR148","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19:715\u2013736. https:\/\/doi.org\/10.1038\/s41582-023-00883-2","journal-title":"Nat Rev Neurol"},{"key":"12253_CR149","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(24)00274-6","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Boxer AL, Lang AE (2024) Clinical versus biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol 23:765\u2013766. https:\/\/doi.org\/10.1016\/S1474-4422(24)00274-6","journal-title":"Lancet Neurol"},{"key":"12253_CR150","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552\u2013563. https:\/\/doi.org\/10.1016\/S1474-4422(17)30157-6","journal-title":"Lancet Neurol"},{"key":"12253_CR151","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","volume":"18","author":"AL Boxer","year":"2019","unstructured":"Boxer AL et al (2019) Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol 18:549\u2013558. https:\/\/doi.org\/10.1016\/S1474-4422(19)30139-5","journal-title":"Lancet Neurol"},{"key":"12253_CR152","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P et al (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1:521\u2013534. https:\/\/doi.org\/10.1038\/s43587-021-00070-2","journal-title":"Nat Aging"},{"key":"12253_CR153","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton NJ et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16:265\u2013284. https:\/\/doi.org\/10.1038\/s41582-020-0348-0","journal-title":"Nat Rev Neurol"},{"key":"12253_CR154","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/brain\/awy079","volume":"141","author":"L Hamelin","year":"2018","unstructured":"Hamelin L et al (2018) Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer\u2019s disease. Brain 141:1855\u20131870. https:\/\/doi.org\/10.1093\/brain\/awy079","journal-title":"Brain"},{"key":"12253_CR155","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12:609\u2013622. https:\/\/doi.org\/10.1016\/S1474-4422(13)70090-5","journal-title":"Lancet Neurol"},{"key":"12253_CR156","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1445-5994.2006.01153.x","volume":"36","author":"DR Williams","year":"2006","unstructured":"Williams DR (2006) Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36:652\u2013660. https:\/\/doi.org\/10.1111\/j.1445-5994.2006.01153.x","journal-title":"Intern Med J"},{"key":"12253_CR157","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/s0317167100012087","volume":"38","author":"M Bouchard","year":"2011","unstructured":"Bouchard M, Suchowersky O (2011) Tauopathies: one disease or many? Can J Neurol Sci 38:547\u2013556. https:\/\/doi.org\/10.1017\/s0317167100012087","journal-title":"Can J Neurol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12253-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:02:49Z","timestamp":1782856969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12253-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12253"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12253-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This article does not contain any studies involving human participants or identifiable personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1030"}}